Recombinant Human Luteinizing Hormone

Phase 3Small molecule

Recombinant Human Luteinizing Hormone is one of 49 small molecule programs targeting Hypogonadotropic Hypogonadism. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hypogonadotropic HypogonadismActive, not recruiting

Ovarian ReserveActive, not recruiting

Hypogonadotropic HypogonadismPhase 3

Active, not recruiting

Ovarian ReservePhase 2

Active, not recruiting

Competition

Competitive Landscape

50 competitors in Ovarian Reserve

#DrugCompanyPhaseTrials

Ulipristal Acetate

AbbVie

Approved

1 2

Folvite

Eli Lilly

Phase 3

1 3

Circadin

NNeurim Pharmaceuticals Ltd.

Phase 3

2 4

Ovitrelle

Merck & Co.

Approved

1 5

Buserelin

NNCIC Clinical Trials Group

Approved

1 6

Human Menopausal Gonadotropin

EMD Serono

Approved

1 7

Dehydroepiandrosterone

IInflabloc Pharmaceuticals

Phase 3

1 8

Trelstar

OOncoVerity, Inc.

Phase 2

1 9

Myoinositol

SSohag University

Phase 3

1 10

Dienogest

Bayer

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Sleep Restriction1 trial

Hormonal Mechanisms of Sleep Restriction - Axis Study

Active, not recruiting·PPeter y. Liu·Phase 1·NCT03142893·80 enrolled

Ovarian Reserve1 trial

A Randomised, Phase II, Comparative Study With a Parallel Control for Evaluating the Efficacy and Safety of Combined Treatment of Lutropin Alpha and Recombinant Human Luteinizing Hormone in the Middle of the Controlled Ovarian Stimulation Follicular Phase in Women With Reduced Ovarian Reserve

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT01110707·131 enrolled

Hypogonadotropic Hypogonadism1 trial

A Study Using Recombinant Human Luteinizing Hormone (r-hLH, Luveris®) in the Treatment of Chinese Women With Hypogonadotropic Hypogonadism

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT01084265·31 enrolled

Postmenopausal Women1 trial

Hormonal Mechanisms of Sleep Restriction - Axis Study in Older Men and Postmenopausal Women

Active, not recruiting·LLundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center·Phase 1·NCT04037605·5 enrolled

Clinical Trial1 trial

A Clinical Trial to Determine the Effect of Lutropin Alfa on Embryo Quality and Implantation Rate in Advanced Reproductive Age

Terminated· Merck & Co. logo

Merck & Co.·Phase 2·NCT01075815·76 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Recombinant Human Luteinizing Hormone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Recombinant Human Luteinizing Hormone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Recombinant Human Luteinizing Hormone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Merck & Co.

Recombinant Human Luteinizing Hormone

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Sleep Restriction1 trial

Ovarian Reserve1 trial

Hypogonadotropic Hypogonadism1 trial

Postmenopausal Women1 trial

Clinical Trial1 trial

References

Drug Info

Quick Facts

Related News